Last reviewed · How we verify
NCT05230186
A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.
trial testing Tumor Biopsy in Solid Tumor, Adult in 200 participants. Status unknown.
23 December 2024
Quick facts
| Lead sponsor | TScan Therapeutics, Inc. |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 26 February 2021 |
| Primary completion | 23 December 2024 |
| Estimated completion | 23 December 2024 |
| Sites | 4 locations across United States |
Drugs / interventions tested
- Tumor Biopsy
Conditions studied
- Solid Tumor, Adult — all drugs for Solid Tumor, Adult →
Sponsor
TScan Therapeutics, Inc. — full company profile →
Who can join
18 and older, any sex, with Solid Tumor, Adult. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
T Cell Receptor-engineered T-cell therapy (TCR T-cell therapy) offers a potentially transformative approach to treating cancer, but is currently limited by the lack of known targets (Maus and June, 2016; Ping et al., 2018). Arguably the most clinically meaningful way to discover new targets and TCRs for TCR T-cell therapy is to study the tumor-infiltrating lymphocytes of patients that are actively responding to immune checkpoint inhibitor (ICI) therapy. These T cells are clonally expanded as a result of checkpoint inhibition and are responsible for the patient's clinical response. The goal of this study is to acquire tumor and blood samples from up to 200 patients with solid tumor malignancies who respond to ICI therapy. T cells will be isolated from these samples and the targets of their TCRs determined using TScan's genome-wide, high-throughput target ID technology. The expected outcome of this study is the discovery of a collection of new targets for TCR T-cell therapy, along with associated TCRs that will then be developed as novel therapies for patients with similar malignancies.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Immune Biomarkers in Triple-Negative Breast Cancer: Improving the Predictivity of Current Testing Methods.
Porta FM, Sajjadi E, Venetis K, Frascarelli C, et al · · 2023 · cited 19× · PMID 37511789 · DOI 10.3390/jpm13071176
Verify or expand the search:
- PubMed search for NCT05230186
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Tumor Biopsy
Trials testing the same drug.
- NCT07447076 — Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT) · Phase 2 · not yet recruiting
- NCT07145177 — 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer · Phase 1 · recruiting
- NCT07217496 — N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer · Phase 1 · withdrawn
- NCT06942104 — Imaging of Solid Tumors Using 18F-TRX · Phase 1 · recruiting
- NCT06061705 — Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aerodigestive · NA · recruiting
Other recruiting trials for Solid Tumor, Adult
Currently open trials in the same condition.
- NCT07139990 — Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM) · Phase 1 · recruiting
- NCT06398418 — R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients · Phase 1 · recruiting
- NCT06682793 — A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor · Phase 1, PHASE2 · recruiting
- NCT07137195 — Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Hebei) · NA · active not recruiting
- NCT06714617 — Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors · Phase 1 · active not recruiting
Other TScan Therapeutics, Inc. trials
Trials by the same sponsor.
- NCT05973487 — A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metasta · Phase 1 · active not recruiting
- NCT05812027 — A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors · active not recruiting
- NCT04680416 — Tissue Collection to ID TCRs From Renal Clear Cell Carcinoma Patients Responding to Immune Checkpoint Inhibitors · withdrawn
- NCT04397900 — Blood Collection Study From COVID-19 Convalescents Previously Hospitalized to Identify Immunogenic Viral Epitopes · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05230186 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by TScan Therapeutics, Inc.
- Last refreshed: 9 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05230186.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing